ACADIA Pharmaceuticals and the University of California at Los Angeles will receive $545,380; Vicore Pharma, Uppsala University and Charité-Universitätsmedizin Berlin will receive $531,300; and Axxam will receive $402,000 for research on therapies to reverse, treat or prevent nervous system damage due to multiple sclerosis. The grants are through the Accelerating Commercial Development Program funded by the National Multiple Sclerosis Society's Fast Forward subsidiary and Merck KGaA division EMD Serono.

Related Summaries